Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:09:41 ON 26 JUN 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:09:46 ON 26 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9
DICTIONARY FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10781442amend.str





chain nodes :
6 7 8 9 11 12 14 16
ring nodes :
1 2 3 4 5
chain bonds :
4-6 5-12 6-7 6-9 7-8 7-11 12-14 14-16
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-12 6-7 6-9 7-8 7-11 12-14 14-16
isolated ring systems :
containing 1 :

G1:H,Ak

G2:N,SO2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:Atom 9:CLASS 11:CLASS
12:CLASS 14:CLASS 16:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

G2 N,SO2

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:10:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1645 TO ITERATE

100.0% PROCESSED     1645 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        30467 TO    35333
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:10:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    33156 TO ITERATE

100.0% PROCESSED    33156 ITERATIONS                               10 ANSWERS
SEARCH TIME: 00.00.02

L3            10 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             166.94     167.15

FILE 'HCAPLUS' ENTERED AT 09:10:39 ON 26 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 26 Jun 2006 VOL 145 ISS 1
FILE LAST UPDATED: 25 Jun 2006 (20060625/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 14 L3

=> d ed abs ibib hitstr 1-14

Appl. -082

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Mar 2005
GI



I



II

AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I (wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHSO2, etc.; T and W are independently selected from H, (cyclo)alkyl, alkoxy, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl]. For instance, thiophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by [2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenyl]amine. The invention compds. were tested for inhibition of human urotensin II-induced Ca2+ mobilization in UTR cells (IC50 > 0.5 μM).

ACCESSION NUMBER: 2005:185392 HCAPLUS
DOCUMENT NUMBER: 142:280229
TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Dazin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005049286	A1	20050303	US 2004-924180	20040823
US 2004180892	A1	20040916	US 2004-781442	20040218
PRIORITY APPLN. INFO.:			US 2003-448791P	P 20030220
			US 2004-781442	A2 20040218

OTHER SOURCE(S): MARPAT 142:280229
IT 847414-56-6P 847414-58-8P 847414-59-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urotensin II receptor antagonists and CCR-9 antagonists)
RN 847414-56-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-58-8 HCAPLUS
CN 3-Thiophenecarboxamide, 4,5-dimethyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-59-9 HCAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 14 Dec 2004

AB Two extensive studies quantifying the ability of topomer shape similarity to forecast a variety of biol. similarities are described. In a prospective trial of "lead hopping", using topomer similarity for virtual screening and queries from the patent literature, biol. assays of 308 selected compds. (representing 0.03% of those available, per assay type) yielded 11 successful "lead hops" in the 13 assays attempted. The hit rate averaged over all assays was 39% ("activity" defined as inhibition ≥20% at 10 μM), significantly greater than an unexpectedly high neg. control hit rate of 15%. The average "Tanimoto 2D fingerprint similarity" between query and "lead hop" structures (0.36) was little more than the Tanimoto similarity between random drug-like structures. Topomer shape and Tanimoto 2D fingerprint similarities were also compared retrospectively, in their tendencies to concentrate together potential and actual drugs reported to belong to the same "activity class", for twenty classes. Among the most similar 3% of structures (corresponding to "≥0.85 Tanimoto" for these structures), an average of 62% of the topomer similar selection possessed a near neighbor belonging to the same activity class, roughly a one-third superiority over the "Tanimoto ≥ 0.85" selection containing 48% actives in avoiding false positives. Conversely, the least similar 75% of structures contained 0.3% actives for topomer similarity vs. 1.0% actives for Tanimoto 2D fingerprint similarity, a 3-fold superiority for topomers in avoiding false negatives.

ACCESSION NUMBER: 2004:1068075 HCAPLUS
DOCUMENT NUMBER: 142:168975
TITLE: "Lead Hopping". Validation of Topomer Similarity as a Superior Predictor of Similar Biological Activities
AUTHOR(S): Cramer, Richard D.; Jilek, Robert J.; Guessregen, Stefan; Clark, Stephanie J.; Wendt, Bernd; Clark, Robert D.
CORPORATE SOURCE: Tripos Discovery Research, Cornwall, EX23 8LY, UK
SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6777-6791
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 832131-75-6, DR 9704611
RL: PAC (Pharmacological activity); BIOL (Biological study)
(validation of topomer similarity as a superior predictor of similar biol. activities of "Lead hopping")
RN 832131-75-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-(2-cyano-4,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Aug 2002
GI



II

AB The title sulfonamides Ar2-SO2-NH-Ar1 [I; Ar1 = (un)substituted 5-6 membered heteroaryl; Ar2 = thienyl, furyl, pyrrolyl] and their pharmaceutically acceptable salts, useful for modulating or altering the activity of the endothelin family of peptides, were prepared and formulated. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, are provided. A table of approx. 300 compds. I, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH2Cl2 reacted with HCl and formaldehyde in the presence of Bu4NBr to give 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3-(4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thiophenecarboxamide gave title compound II, which was isolated as the free acid, dissolved in EtOAc, and treated with saturated aqueous NaHCO3, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amount of Na2HPO4 in aqueous MeCN gave the salt II.H3PO4.2Na. A solution of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solubility and stability in various aqueous media, such as Labrasol, compared to the free acid II.

ACCESSION NUMBER: 2002:610408 HCAPLUS
DOCUMENT NUMBER: 137:154844
TITLE: Preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders
INVENTOR(S): Wu, Chengde; Blok, Natalie; Patricia, Woodard Timothy; Keller, Karin; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 65 pp., Cont.-in-part of U.S. 6,248,767.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6432994	B1	20020813	US 2000-403599	20000327

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 5783705	A	19980721	US 1997-847797	19970428
US 6248767	B1	20010619	US 1997-938444	19970926
WO 9849162	A1	19981105	WO 1998-US6680	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2002091270	A1	20020711	US 2001-29561	20011220
US 6683103	B2	20040127		

PRIORITY APPLN. INFO.:

US 1997-847797	A2	19970428
US 1997-938444	A2	19970926
WO 1998-US6680	W	19980402
US 2000-403599	A3	20000327

OTHER SOURCE(S): MARPAT 137:154844
IT **184035-85-6P**, N-(3,4-Dimethyl-5-isoxazolyl))-3-(phenylaminocarbonyl)thiophene-2-sulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 271 THERE ARE 271 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 17 Jul 2002
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Thienyl-, furyl-, and pyrrolylsulfonamides, formulations of pharmaceutically acceptable salts thereof, and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, disclosures include N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar2SO2NHAr1 [I; wherein Ar1 = (un)substituted monocyclic or polycyclic heteroaryl, particularly isoxazolyl; Ar2 = G1 or G2; M = (CH2)mCO(CH2)n, (CH2)mCONH(CH2)n, (CH2)mCH:CH(CH2)n, (CH2)mCO(CH2)pNH(CH2)n, C:N(OH)(CH2)n, (CH2)mCO(CH:CH)pNH(CH2)n,CH(OH)(CH2)n, CH(CH)CO(CH2)n, CH(CH3)CO(CH2)mCH:CH(CH2)n, (CH2)n, (CH2)nO, CH2SO0-2, or CO2; m, n, and p = independently 0-6; R1-R5 = independently H, OH, NO2, CN, halo, alkyl, alkenyl, alkynyl, (hetero)aryl, arylalkyl, alkylamino, alkylthio, haloalkyl, alkoxy, alkylsulfonyl, (un)substituted amino, carbamoyl, etc.; or 2 adjacent R1-R5 form alkylenedioxy, alkylenethioxyoxy, or alkylenedithioxy; with provisos; X = S, O, or NR11; R11 = H, (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, heterocyclyl, aralkyl, aralkoxy, alkylalkenyl, alkylalkynyl, OH, CN, acyl, acyloxy, carboxy, SH, NHOH, (un)substituted amino, carbamoyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include hypertension, cardiovascular disease, asthma, hypertension, inflammatory disease, glaucoma, etc. Twenty synthetic examples are given, and numerous example compds. were prepared, tested, and/or claimed. For instance, 3-cyanomethyl-2,4,6-trimethylaniline was treated with H2SO4 in MeOH to give Me 3-amino-2,4,6-trimethylphenylacetate (88%). Amidation with N-(4-chloro-3-methyl-5-isoxazolyl)-3-sulfamoylthiophene-2-carboxylic acid using 1,1'-carbonyldiimidazole in DMF afforded II (15%). The similarly prepared title compound III exhibited IC50 values of 0.0015 ± 0.0014 μM for ETA receptors and 0.324 ± 0.78 μM for ETB receptors. Claimed compds. also exhibited improved oral half-life, bioavailability, and/or in vivo activity over those disclosed previously.

ACCESSION NUMBER: 2002:534073 HCAPLUS
DOCUMENT NUMBER: 137:93741
TITLE: Preparation of N-isoxazolyl aryl-substituted thienyl-, furyl-, and pyrrolylsulfonamides and derivatives as endothelin activity modulators
INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Blok, Natalie
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 59 pp., Cont.-in-part of U. S. 5,962,490.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6420567	B1	20020716	US 1997-938325	19970926
US 5962490	A	19991005	US 1996-721183	19960927
AU 9935803	A1	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 2002091272	A1	20020711	US 2001-11610	20011105
US 6632829	B2	20031014		
US 2003208084	A1	20031106	US 2003-447763	20030528

PRIORITY APPLN. INFO.:

US 1996-721183	A2	19960927
US 1987-100865	A2	19870925
US 1990-416199	A2	19900515
US 1993-65202	B2	19930520
US 1993-100125	B2	19930730
US 1993-100565	A2	19930730
US 1993-142159	A2	19931021
US 1993-142552	A2	19931021
US 1993-142631	B2	19931021
US 1994-222287	A2	19940405
US 1994-247072	A2	19940520
US 1995-417075	A2	19950404
US 1995-477223	A2	19950606
AU 1996-55367	A	19960404
WO 1996-US4759	A2	19960404
US 1997-938325	A3	19970926
US 2001-11610	A3	20011105

OTHER SOURCE(S): MARPAT 137:93741
IT **184035-85-6P**, N-(3,4-Dimethyl-5-isoxazolyl)-3-(phenylaminocarbonyl)thiophene-2-sulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(endothelin modulator; preparation of N-isoxazolyl aryl-substituted thienyl-, furyl-, and pyrrolylsulfonamides and derivs. as endothelin activity modulators)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Apr 2002
GI



I II III

AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
DOCUMENT NUMBER: 136:309843
TITLE: Preparation of thiophenes as phosphate transport inhibitors
INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028353	A2	20020411	WO 2001-US31318	20011005
WO 2002028353	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002013048	A5	20020415	AU 2002-13048	20011005
PRIORITY APPLN. INFO.:			US 2000-238068P	P 20001005
			WO 2001-US31318	W 20011005

OTHER SOURCE(S): MARPAT 136:309843
IT 409364-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenes as phosphate transport inhibitors)
RN 409364-73-4 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-2-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Jul 2001
AB Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods are also provided for the treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and metabolic bone disorders; climacteric disorders, including hot flushes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders associated with the reduction in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists.

ACCESSION NUMBER: 2001:507533 HCAPLUS
DOCUMENT NUMBER: 135:102580
TITLE: Pharmaceutical and veterinary uses of endothelin antagonists for treatment of laminitis and other conditions, and preparation thereof
INVENTOR(S): Brock, Thomas A.; Ward, Patrick R.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049289	A1	20010712	WO 2000-US35280	20001227

W: AE, AG, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001024567	A5	20010716	AU 2001-24567	20001227
PRIORITY APPLN. INFO.:			US 1999-174125P	P 19991231
			WO 2000-US35280	W 20001227

OTHER SOURCE(S): MARPAT 135:102580
IT 184035-85-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonists for veterinary or pharmaceutical use in treatment of laminitis and other conditions)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 Jun 2001
GI



II

AB Formulations of pharmaceutically acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations, are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor, by contacting the receptor with the sulfonamide salt, are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more of these sulfonamide salts or prodrugs thereof, that inhibit or increase the activity of endothelin, are also provided. In particular, pharmaceutically acceptable salts of compds. Ar2-SO2-NH-Ar1 [I; where Ar1 = 5-membered heteroaryl; Ar2 = thienyl or thionaphthyl; salt is with an alkali metal or mineral acid] are claimed. A table of approx. 300 compds. I, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH2Cl2 reacted with HCl and formaldehyde in the presence of Bu4NBr to give 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3-(4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thiophenecarboxamide gave title compound II, which was isolated as the free acid, dissolved in EtOAc, and treated with saturated aqueous NaHCO3, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amount of Na2HPO4 in aqueous MeCN gave the salt II.H3PO4.2Na. A solution of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solubility and stability in various aqueous media, such as Labrasol, compared to the free acid II.

ACCESSION NUMBER: 2001:449271 HCAPLUS
DOCUMENT NUMBER: 135:46080
TITLE: Formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders
INVENTOR(S): Blok, Natalie; Wu, Chengde; Woodard, Patricia; Keller, Karin; Kogan, Timothy
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: U.S., 58 pp., Cont.-in-part of U.S. 5,783,705.

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6248767	B1	20010619	US 1997-938444	19970926
US 5783705	A	19980721	US 1997-847797	19970428
CA 2281090	AA	19981105	CA 1998-2281090	19980402
CA 2281090	C	20050607		
CA 2496680	AA	19981105	CA 1998-2496680	19980402
WO 9849162	A1	19981105	WO 1998-US6680	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9869504	A1	19981124	AU 1998-69504	19980402
AU 749167	B2	20020620		
EP 980369	A1	20000223	EP 1998-915281	19980402
EP 980369	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900469	A	20000615	EE 1999-469	19980402
EE 4156	B1	20031015		
BR 9812258	A	20000725	BR 1998-12258	19980402
TR 9902401	T2	20000821	TR 1999-2401	19980402
NZ 336898	A	20011026	NZ 1998-336898	19980402
JP 2001520643	T2	20011030	JP 1998-540982	19980402
JP 3455233	B2	20031014		
TR 200101905	T2	20020621	TR 2001-200101905	19980402
TR 200202738	T2	20030321	TR 2002-200202738	19980402
JP 2003176288	A2	20030624	JP 2002-352236	19980402
EE 200300214	A	20030815	EE 2003-200300214	19980402
SG 100766	A1	20031226	SG 2001-200106590	19980402
SG 100767	A1	20031226	SG 2001-200106591	19980402
IL 131318	A1	20040831	IL 1998-131318	19980402
EP 1498418	A1	20050119	EP 2004-24998	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
EP 1498419	A1	20050119	EP 2004-24999	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
IL 156977	A1	20050320	IL 1998-156977	19980402
AT 292129	E	20050415	AT 1998-915281	19980402
CN 1636994	A	20050713	CN 2004-10092312	19980402
ES 2241133	T3	20051016	ES 1998-915281	19980402
NO 9905221	A	19991228	NO 1999-5221	19991026
MX 9909860	A	20000331	MX 1999-9860	19991027
US 6432994	B1	20020813	US 2000-403599	20000327
HK 1028033	A1	20050506	HK 2000-107366	20001117
US 2001039289	A1	20011108	US 2001-792237	20010223
US 6458805	B2	20021001		

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 2002091270	A1	20020711	US 2001-29561	20011220
US 6683103	B2	20040127		

PRIORITY APPLN. INFO.:

US 1997-847797	A2 19970428
US 1997-938444	A 19970926
CA 1998-2281090	A3 19980402
EE 1999-469	A 19980402
EP 1998-915281	A3 19980402
IL 1998-131318	A3 19980402
JP 1998-540982	A3 19980402
WO 1998-US6680	W 19980402
US 2000-403599	A3 20000327

OTHER SOURCE(S): MARPAT 135:46080
IT 184035-85-6P, N-(3,4-Dimethyl-5-isoxazolyl))-3-(phenylaminocarbonyl)thiophene-2-sulfonamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study)); PREP (Preparation); USES (Uses)
(drug candidate; preparation and formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 219 THERE ARE 219 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Oct 1999
GI



II



III

AB Thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides, are provided. In particular, the disclosure includes N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar2SO2NHAr1 [I; Ar1 = (un)substituted aryl, particularly isoxazolyl; Ar2 = biol. effective group for inhibiting endothelin binding by ≥ 50% at ≤100 μM, notably thienyl, furyl, pyrrolyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include hypertension, cardiovascular disease, asthma, hypertension, inflammatory disease, glaucoma, etc. Approx. 190 synthetic examples are given, and numerous example compds. were prepared, tested, and/or claimed. For instance, 5-amino-4-bromo-3-methylisoxazole was treated with NaH in THF, followed by thiophene-2-sulfonyl chloride, to give 34% title compound II. The similarly prepared title compound III had IC50 values of 0.024 μM for ETA receptors and 7.95 μM for ETB receptors, indicating substantial selectivity for ETA.

ACCESSION NUMBER: 1999:640160 HCAPLUS
DOCUMENT NUMBER: 131:271803
TITLE: Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
INVENTOR(S): Chan, Ming Fai; Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Kois, Adam; Verner, Erik Joel; Castillo, Rosario Silvestre; Yalamorri, Venkatachalapathi; Balaji, Vitukudi Narayanaiyengar
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 477,223.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962490	A	19991005	US 1996-721183	19960927
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
US 5591761	A	19970107	US 1994-222287	19940405
US 5571821	A	19961105	US 1994-247072	19940520
US 5594021	A	19970114	US 1995-477223	19950606

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

WO 9631492		A1	19961010	WO 1996-US4759	19960404
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2261760		AA	19980402	CA 1997-2261760	19970926
CA 2261760		C	20050329		
WO 9813366		A1	19980402	WO 1997-US17402	19970926
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9745059		A1	19980417	AU 1997-45059	19970926
AU 736269		B2	20010726		
EP 946552		A1	19991006	EP 1997-943629	19970926
EP 946552		B1	20040707		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1231664		A	19991013	CN 1997-198343	19970926
BR 9711550		A	20000118	BR 1997-11550	19970926
JP 2000507607		T2	20000620	JP 1998-515979	19970926
JP 3743520		B2	20060208		
NZ 334797		A	20010223	NZ 1997-334797	19970926
US 6420567		B1	20020716	US 1997-938325	19970926
JP 2002308875		A2	20021023	JP 2002-101613	19970926
EP 1342721		A1	20030910	EP 2003-7240	19970926
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
AT 270669		E	20040715	AT 1997-943629	19970926
CN 1530366		A	20040922	CN 2003-2003158478	19970926
PT 946552		T	20041029	PT 1997-943629	19970926
ES 2224271		T3	20050301	ES 1997-943629	19970926
NO 9901388		A	19990527	NO 1999-1388	19990322
US 6331637		B1	20011218	US 1999-274280	19990322
KR 2000048681		A	20000725	KR 1999-702629	19990326
AU 9935803		A1	19990916	AU 1999-35803	19990622
AU 726595		B2	20001116		
US 2002091272		A1	20020711	US 2001-11610	20011105
US 6632829		B2	20031014		
US 2003208084		A1	20031106	US 2003-447763	20030528
PRIORITY APPLN. INFO.:				US 1987-100865	A2 19870925
				US 1990-416199	A2 19900515
				US 1993-65202	B2 19930520
				US 1993-100125	B2 19930730
				US 1993-100565	A2 19930730
				US 1993-142159	A2 19931021
				US 1993-142552	A2 19931021
				US 1993-142631	B2 19931021
				US 1994-222287	A2 19940405
				US 1994-247072	A2 19940520
				US 1995-417075	A2 19950404
				US 1995-477223	A2 19950606

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	WO 1996-US4759	A2	19960404
	US 1995-416199	A	19950404
	AU 1996-55367	A	19960404
	US 1996-721183	A	19960927
	EP 1997-943629	A3	19970926
	JP 1998-515979	A3	19970926
	US 1997-938325	A3	19970926
	WO 1997-US17402	W	19970926
	US 2001-11610	A3	20011105

OTHER SOURCE(S): MARPAT 131:271803

IT 184041-00-7P, N-[(2-Methoxyethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-3-[(phenylamino)carbonyl]-5-(trimethylsilyl)thiophene-2-sulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thienyl-, furyl- and pyrrolyl-based sulfonamides and analogs as endothelin agonists and antagonists)

RN 184041-00-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]-N-phenyl-5-(trimethylsilyl)- (9CI) (CA INDEX NAME)



IT 184035-85-6P, N-(3,4-Dimethyl-5-isoxazolyl)-3-[(phenylamino)carbonyl]thiophene-2-sulfonamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of thienyl-, furyl- and pyrrolyl-based sulfonamides and analogs as endothelin agonists and antagonists)

RN 184035-85-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 13 Nov 1998

AB R2SO2NHR1 [I; R1 = bi- or tricycloalkyl, heterocyclyl, (hetero)aryl; R2 = CH:CHPh, thienyl, (iso)quinolyl, indolyl, etc.] were prepared Thus, 5-amino-4-bromo-3-methylisoxazole was amidated by thiophene-2-sulfonyl chloride to give I (R1 = 4-bromo-3-methyl-5-isoxazolyl, R2 = 2-thienyl). Data for biol. activity of I were given.

ACCESSION NUMBER: 1998:721695 HCAPLUS

DOCUMENT NUMBER: 129:343488

TITLE: Preparation of heteroaromatic sulfonamides as endothelin antagonists

INVENTOR(S): Wu, Chengde; Blok, Natalie; Kogan, Timothy; Keller, Karin; Woodard, Patricia

PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA

SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849162	A1	19981105	WO 1998-US6680	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5783705	A	19980721	US 1997-847797	19970428
US 6248767	B1	20010619	US 1997-938444	19970926
CA 2281090	AA	19981105	CA 1998-2281090	19980402
CA 2281090	C	20050607		
AU 9869504	A1	19981124	AU 1998-69504	19980402
AU 749167	B2	20020620		
EP 980369	A1	20000223	EP 1998-915281	19980402
EP 980369	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900469	A	20000615	EE 1999-469	19980402
EE 4156	B1	20031015		
BR 9812258	A	20000725	BR 1998-12258	19980402
NZ 336898	A	20011026	NZ 1998-336898	19980402
JP 2001520643	T2	20011030	JP 1998-540982	19980402
JP 3455233	B2	20031014		
IL 131318	A1	20040831	IL 1998-131318	19980402
IL 156977	A1	20050320	IL 1998-156977	19980402
AT 292129	E	20050415	AT 1998-915281	19980402
NO 9905221	A	19991228	NO 1999-5221	19991026
MX 9909860	A	20000331	MX 1999-9860	19991027
US 6432994	B1	20020813	US 2000-403599	20000327
HK 1028033	A1	20050506	HK 2000-107366	20001117

PRIORITY APPLN. INFO.:	US 1997-847797	A	19970428
	US 1997-938444	A	19970927
	IL 1998-131318	A3	19980402
	WO 1998-US6680	W	19980402

OTHER SOURCE(S): MARPAT 129:343488

IT 184035-85-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroarom. sulfonamides as endothelin antagonists)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Apr 1998
GI



I

AB R1SO2NHR [I; R = (un)substituted (hetaro)aryl; R1 = R2Z2Z1; R2 = (un)substituted Ph; Z1 = thiophene-, furan-, pyrrole-2,3- or -3,2-diyl, etc.; Z2 = COCH2, CONH, CO2, CH:CH, CH2O, etc.] were prepared Thus, 2-methoxycarbonyl-3-thiophenesulfonyl chloride was amidated by 5-amino-4-chloro-3-methylisoxazole and the product converted in 5 steps to title compound II. Data for biol. activity of I were given.

ACCESSION NUMBER: 1998:210751 HCAPLUS
DOCUMENT NUMBER: 128:270601
TITLE: Preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators
INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy P.; Blok, Natalie; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813366	A1	19980402	WO 1997-US17402	19970926
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5962490	A	19991005	US 1996-721183	19960927
CA 2261760	AA	19980402	CA 1997-2261760	19970926
CA 2261760	C	20050329		
AU 9745059	A1	19980417	AU 1997-45059	19970926
AU 736269	B2	20010726		
EP 946552	A1	19991006	EP 1997-943629	19970926
EP 946552	B1	20040707		

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9711550	A	20000118	BR 1997-11550	19970926
JP 2000507607	T2	20000620	JP 1998-515979	19970926
JP 3743520	B2	20060208		
NZ 334797	A	20010223	NZ 1997-334797	19970926
AT 270669	E	20040715	AT 1997-943629	19970926
NO 9901388	A	19990527	NO 1999-1388	19990322
AU 9935803	A1	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		
PRIORITY APPLN. INFO.:			US 1996-721183	A 19960927
			US 1987-100865	A2 19870925
			US 1990-416199	A2 19900515
			US 1993-65202	B2 19930520
			US 1993-100125	B2 19930730
			US 1993-100565	A2 19930730
			US 1993-142159	A2 19931021
			US 1993-142552	A2 19931021
			US 1993-142631	B2 19931021
			US 1994-222287	A2 19940405
			US 1994-247072	A2 19940520
			US 1995-417075	A2 19950404
			WO 1995-477223	A2 19950606
			AU 1996-55367	A 19960404
			WO 1996-US4759	A2 19960404
			WO 1997-US17402	W 19970926

OTHER SOURCE(S): MARPAT 128:270601
IT 184035-85-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Feb 1997
GI



II III

AB Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. The compds. include sulfonamides Ar2SO2NHAr1 [I; Ar1 = (un)substituted (cyclo)alk(en/yn)yl, aryl, heterocyclyl, bi- or tricyclyl; Ar2 = (un)substituted thienyl, furyl, pyrrolyl, benzothienyl, benzofuryl, indolyl]. In particular, N-(isoxazolyl) amides, and methods using them to inhibit binding of endothelin peptides to endothelin receptors, are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more compds. I, or prodrugs thereof, are also provided. Over 160 synthetic examples and the results of a variety of bioassays are given. For instance, amidation of thiophene-2-sulfonyl chloride with 5-amino-4-bromo-3-methylisoxazole after treatment of the latter with NaH in dry THF gave 34% of the amide II. In an endothelin receptor assay, the amide III had IC50 values of 0.0006 μM and 1.99 μM at ETA and ETB receptors, resp.

ACCESSION NUMBER: 1997:97729 HCAPLUS
DOCUMENT NUMBER: 126:171477
TITLE: Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
INVENTOR(S): Chan, Ming F.; Raju, Bore G.; Kois, Adam; Verner, Erik J.; Wu, Chengde; Castillo, Rosario S.; Yalamoori, Venkatachalapathi; Balaji, Vitukudi N.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 77 pp., Cont.-in-part of U.S. Ser. No. 247,072.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5594021	A	19970114	US 1995-477223	19950606
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
US 5591761	A	19970107	US 1994-222287	19940405
US 5571821	A	19961105	US 1994-247072	19940520
CA 2217169	AA	19961010	CA 1996-2217169	19960404
CA 2217169	C	20050329		
CA 2288439	AA	19961010	CA 1996-2288439	19960404
CA 2288439	C	20030401		

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CA 2420614		AA	19961010	CA 1996-2420614	19960404
WO 9631492		A1	19961010	WO 1996-US4759	19960404
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9655367		A1	19961023	AU 1996-55367	19960404
AU 711968		B2	19991028		
EP 819125		A1	19980121	EP 1996-912600	19960404
EP 819125		B1	20030618		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1184470		A	19980610	CN 1996-193973	19960404
CN 1130355		B	20031210		
JP 11507015		T2	19990622	JP 1996-530524	19960404
JP 3233642		B2	20011126		
NZ 306734		A	20000128	NZ 1996-306734	19960404
NZ 500282		A	20000128	NZ 1996-500282	19960404
EP 1048657		A1	20001102	EP 2000-113076	19960404
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2002030075		A2	20020129	JP 2001-171692	19960404
JP 3527217		B2	20040517		
AT 243203		E	20030715	AT 1996-912600	19960404
PT 819125		T	20031128	PT 1996-912600	19960404
ES 2201181		T3	20040316	ES 1996-912600	19960404
PL 186854		B1	20040331	PL 1996-322707	19960404
US 5962490		A	19991005	US 1996-721183	19960927
TW 492966		B	20020701	TW 1996-85112218	19961004
NO 9704577		A	19971204	NO 1997-4577	19971003
NO 315607		B1	20030929		
MX 9707630		A	20000331	MX 1997-7630	19971003
HK 1001769		A1	20040130	HK 1998-100844	19980205
US 6331637		B1	20011218	US 1999-274280	19990322
AU 9935803		A1	19990916	AU 1999-35803	19990622
AU 726595		B2	20001116		
US 2002095041		A1	20020718	US 2001-6256	20011204
US 6613804		B2	20030902		
JP 2004043495		A2	20040212	JP 2003-318261	20030910
PRIORITY APPLN. INFO.:				US 1993-65202	B2 19930520
				US 1993-100125	B2 19930730
				US 1993-100565	B2 19930730
				US 1993-142159	A2 19931021
				US 1993-142552	A2 19931021
				US 1993-142631	B2 19931021
				US 1994-222287	A2 19940405
				US 1994-247072	A2 19940520
				US 1995-417075	B2 19950404
				US 1987-100865	A2 19870925
				US 1990-416199	A2 19900515
				US 1995-416199	A 19950404
				US 1995-477223	A 19950606
				AU 1996-55367	A 19960404
				CA 1996-2217169	A3 19960404
				EP 1996-912600	A3 19960404
				JP 1996-530524	A3 19960404

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	JP 2001-171692	A3	19960404
	WO 1996-US4759	W	19960404
	US 1996-721183	A1	19960927
	US 1997-913331	A3	19971107

OTHER SOURCE(S): MARPAT 126:171477

IT **184041-00-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic sulfonamides as endothelin agonists and antagonists)

RN 184041-00-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]-N-phenyl-5-(trimethylsilyl)- (9CI) (CA INDEX NAME)



IT **184035-85-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic sulfonamides as endothelin agonists and antagonists)

RN 184035-85-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 06 Feb 1997

AB Thiophenyl-, furyl-, and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, isoxazolyl-thiophenyl-sulfonamides, isoxazolyl-furyl-sulfonamides and isoxazolyl-pyrrolyl-sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

ACCESSION NUMBER:	1997:85523 HCAPLUS
DOCUMENT NUMBER:	126:166488
TITLE:	Thiophenyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
INVENTOR(S):	Chan, Ming F.; Raju, Bore G.; Kois, Adam; Verner, Erik J.; Wu, Chengde; Castillo, Rosario S.; Yalamoori, Venkatachalapathi; Balaji, Vitukudi N.
PATENT ASSIGNEE(S):	Texas Biotechnology Corporation, USA
SOURCE:	U.S., 29 pp., Cont.-in-part of U.S. 5,514,691. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	10
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5591761	A	19970107	US 1994-222287	19940405
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
CA 2161346	AA	19941208	CA 1994-2161346	19940520
CA 2161346	C	20041123		
WO 9427979	A1	19941208	WO 1994-US5755	19940520
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9469646	A1	19941220	AU 1994-69646	19940520
AU 691813	B2	19980528		
GB 2285625	A1	19950719	GB 1995-3693	19940520
GB 2285625	B2	19971210		
EP 699191	A1	19960306	EP 1994-918081	19940520
EP 699191	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5571821	A	19961105	US 1994-247072	19940520
JP 08510744	T2	19961112	JP 1995-500856	19940520
EP 870764	A1	19981014	EP 1998-109339	19940520
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 174592	E	19990115	AT 1994-918081	19940520
ES 2127397	T3	19990416	ES 1994-918081	19940520
RU 2151144	C1	20000620	RU 1995-121744	19940520
EP 1069114	A2	20010117	EP 2000-119107	19940520
EP 1069114	A3	20010131		
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 5594021	A	19970114	US 1995-477223	19950606
US 5962490	A	19991005	US 1996-721183	19960927
US 6030991	A	20000229	US 1996-730633	19961206
AU 9860585	A1	19980604	AU 1998-60585	19980331
AU 724575	B2	20000928		

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 6331637	B1	20011218	US 1999-274280	19990322
AU 9935803	A1	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		
US 2001036958	A1	20011101	US 2000-749716	20001227
US 6541498	B2	20030401		
PRIORITY APPLN. INFO.:			US 1993-65202	B2 19930520
			US 1993-100125	B2 19930730
			US 1993-100565	B2 19930730
			US 1993-142159	A2 19931021
			US 1993-142552	A2 19931021
			US 1993-142631	B2 19931021
			US 1987-100865	A2 19870925
			US 1990-416199	A2 19900515
			US 1994-222287	A 19940405
			EP 1994-918081	A3 19940520
			EP 1998-109339	A3 19940520
			US 1994-247072	A2 19940520
			WO 1994-US5755	W 19940520
			US 1995-416199	B1 19950404
			US 1995-417075	B2 19950404
			US 1995-477223	A2 19950606
			AU 1996-55367	A 19960404
			WO 1996-US4759	A2 19960404
			US 1996-721183	A1 19960927
			US 1996-730633	A1 19961206
			US 1999-439802	A1 19991112

OTHER SOURCE(S): MARPAT 126:166488

IT **187218-38-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides and modulation of endothelin binding to receptor and treatment of endothelin-mediated disorders)

RN 187218-38-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01 Jan 1997
GI



AB R2SO2NHR1 [I; R1 = (hetero)aryl; R2 = (un)substituted biphenylyl, -2- or -3-furyl, -thienyl, -pyrrolyl] were prepared Thus, 5-amino-4-bromo-3-methylisoxazole (preparation given) was amidated by thiophene-2-sulfonyl chloride to give title compound II. Data for biol. activity of I were given.

ACCESSION NUMBER: 1996:761669 HCAPLUS
DOCUMENT NUMBER: 126:31342
TITLE: Preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin receptor antagonists
INVENTOR(S): Chan, Ming Fai; Raju, Bore Gowda; Kois, Adam; Verner, Erik Joel; Wu, Chengde; Castillo, Rosario Silverstre; Yalamoori, Venkatachalapathi; Balaji, Vitukudi Narayanaiyenga
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9631492	A1	19961010	WO 1996-US4759	19960404
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5594021	A	19970114	US 1995-477223	19950606
AU 9655367	A1	19961023	AU 1996-55367	19960404
AU 711968	B2	19991028		
EP 819125	A1	19980121	EP 1996-912600	19960404
EP 819125	B1	20030618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9604875	A	19980519	BR 1996-4875	19960404
JP 11507015	T2	19990622	JP 1996-530524	19960404
JP 3233642	B2	20011126		
NZ 306734	A	20000128	NZ 1996-306734	19960404
AT 243203	E	20030715	AT 1996-912600	19960404
PL 186854	B1	20040331	PL 1996-322707	19960404
US 5962490	A	19991005	US 1996-721183	19960927
NO 9704577	A	19971204	NO 1997-4577	19971003

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

NO 315607	B1	20030929		
MX 9707630	A	20000331	MX 1997-7630	19971003
US 2001021714	A1	20010913	US 1997-913331	19971107
US 6342610	B2	20020129		
HK 1001769	A1	20040130	HK 1998-100844	19980205
US 6331637	B1	20011218	US 1999-274280	19990322
AU 9935803	A1	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		
US 2002091272	A1	20020711	US 2001-11610	20011105
US 6632829	B2	20031014		

PRIORITY APPLN. INFO.:

US 1995-416199	A	19950404
US 1995-417075	A	19950404
US 1995-477223	A	19950606
US 1987-100865	A2	19870925
US 1990-416199	A2	19900515
US 1993-65202	B2	19930520
US 1993-100125	B2	19930730
US 1993-100565	B2	19930730
US 1993-142159	A2	19931021
US 1993-142552	A2	19931021
US 1993-142631	B2	19931021
US 1994-222287	A2	19940405
US 1994-247072	A2	19940520
AU 1996-55367	A	19960404
WO 1996-US4759	W	19960404
US 1996-721183	A1	19960927
US 1997-938325	A3	19970926

OTHER SOURCE(S): MARPAT 126:31342

IT **184035-85-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin receptor antagonists)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



IT **184041-00-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin receptor antagonists)
RN 184041-00-7 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]-N-phenyl-5-(trimethylsilyl)- (9CI)

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 20 Apr 1985
GI



I

AB Blue dyes were prepared having the general formula I (R = CN, alkoxycarbonyl, alkoxyalkoxycarbonyl, alkenyloxycarbonyl, CONHR4, COR4; R1 = H, C1-4 alkyl, phenyl; R2 = NO2, CN, alkoxycarbonyl, CONHR4, COR4; R3 = (un)substituted aminophenyl, aminoquinolyl, aminonaphthyl; R4 = H, C1-6 alkyl, phenyl). Thus, 2-amino-5-(2,2-dicyanovinyl)-3-nitrothiophene [95551-97-6] was diazotized and coupled with N,N-diethyl-m-toluidine [91-67-8] to give I [R = CN; R1 = H; R2 = NO2; R3 = 2,4-Me(Et2N)C6H3] [95551-98-7].

ACCESSION NUMBER: 1985:133543 HCAPLUS
DOCUMENT NUMBER: 102:133543
TITLE: Monoazo disperse dyes for polyester fibers
PATENT ASSIGNEE(S): Gosei Senryo Gijutsu Kenkyu Kumiai, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59204658	A2	19841120	JP 1983-79360	19830509
JP 03016983	B4	19910306		

PRIORITY APPLN. INFO.:

JP 1983-79360		19830509

IT **95551-77-2**
RL: TEM (Technical or engineered material use); USES (Uses)
(dye, blue, for polyester fibers)
RN 95551-77-2 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[7-(acetylamino)-1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2,2,4-trimethyl-6-quinolinyl]azo]-4-butyl-5-(2-cyanoethenyl)-N-phenyl- (9CI) (CA INDEX NAME)



```
=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    74.07     241.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -10.50     -10.50

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:11:28 ON 26 JUN 2006
```

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak
G2 N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:02:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 267 TO ITERATE

100.0% PROCESSED 267 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4360 TO 6320
PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:02:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5528 TO ITERATE

100.0% PROCESSED 5528 ITERATIONS 228 ANSWERS
SEARCH TIME: 00.00.01

L3 228 SEA SSS FUL L1

```
=> fil hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     167.15

FILE 'HCAPLUS' ENTERED AT 13:02:10 ON 26 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Jun 2006  VOL 145 ISS 1
FILE LAST UPDATED: 25 Jun 2006  (20060625/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4            5 L3

=> d ed abs ibib hitstr 1-5

L4   ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2006 ACS on STN
ED   Entered STN:  04 Mar 2005
GI
```



I



II

AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I [wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHSO2, etc.; T and W are independently selected from H, (cyclo)alkyl, alkoxy, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl]. For instance, thiophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by [2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenyl]amine. The invention compds. were tested for inhibition of human urotensin II-induced Ca2+ mobilization in UTR cells (IC50 > 0.5 μM).

ACCESSION NUMBER: 2005:185392 HCAPLUS
DOCUMENT NUMBER: 142:280229
TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005049286	A1	20050303	US 2004-924180		20040823
US 2004180892	A1	20040916	US 2004-781442		20040218
PRIORITY APPLN. INFO.:			US 2003-448791P	P	20030220
			US 2004-781442	A2	20040218

OTHER SOURCE(S): MARPAT 142:280229

IT **749268-37-9P 749268-38-0P 847414-20-4P**
847414-21-5P 847414-22-6P 847414-24-8P
847414-26-0P 847414-27-1P 847414-30-6P
847414-31-7P 847414-33-9P 847414-34-0P
847414-35-1P 847414-36-2P 847414-37-3P
847414-38-4P 847414-39-5P 847414-40-8P
847414-41-9P 847414-42-0P 847414-43-1P
847414-44-2P 847414-45-3P 847414-46-4P
847414-47-5P 847414-48-6P 847414-49-7P
847414-50-0P 847414-51-1P 847414-52-2P
847414-53-3P 847414-60-2P 847414-61-3P
847414-62-4P 847414-63-5P 847414-64-6P
847414-65-7P 847414-67-9P 847414-70-4P
847414-71-5P 847414-72-6P 847414-73-7P
847414-74-8P 847414-75-9P 847414-77-1P
847414-80-6P 847414-82-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urotensin II receptor antagonists and CCR-9 antagonists)

RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-20-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 847414-21-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 847414-22-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(methoxymethyl)(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-24-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-26-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-27-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-30-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-31-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-33-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-34-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-35-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-36-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-37-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-38-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-39-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-40-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-41-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-42-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-43-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-44-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-45-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-46-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-47-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-48-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,5-dichlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-49-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,5-difluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-50-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-dichlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-51-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-52-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-53-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4,5-trifluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-60-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,6-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-61-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,4-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-62-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-63-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-64-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-65-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-bromo-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-67-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-70-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopropyl-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-71-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 847414-72-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 847414-73-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)



RN 847414-74-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-75-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,2',4,6,6'-pentamethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-77-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(diethylamino)-2,4,6-trimethylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-80-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-methoxy-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-82-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[methyl(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Sep 2004
GI



I



II



III

AB The title compds. I and II [R1, R2, R3 = H, halo, alkyl, aryl, aralkyl, CN, CF3, etc.; X = N, CH2, or O; Y = SO2, CO, CH2SO2, CH2CO, NHCO, OCO, or NHSO2; R4 = alkyl, aralkyl or (hetero)aryl, R5 = R1, or Z-NR7R8, or R4, R5 taken together with N can form a 5 or 6 membered ring; Z = (CH2)n, where n = 0-6; R6 = (hetero)aryl, Z-NR7R8; R7, R8 = H, alkyl, aryl, aralkyl or together with N form a pyrrolidine, piperazine, piperidine, or morpholine ring; E = substituted amino, O, S, CR13=CR14, or CR13=N, where R13, R14 = alkyl, (hetero)aryl, halo, OH, alkoxy, etc.; D = substituted amino, O, or S; Z = NR15 or CR15R15 where each R15 = H, alkyl, aryl, or heteroaryl; A = (substituted)amino, CO, or SO2; when A =(substituted)amino, B = SO2, CO2, or C16R16, where R16 = H, alkyl, aryl, or heteroaryl; when A = CO or SO2, B = (substituted)amino; R9, R10 = H, alkyl, (hetero)aryl, halo, OH, Alkoxy, or (substituted)amino; R11, R12 = H, alkyl, or (hetero)aryl] were prepared as urotensin-II receptor antagonists and CCR-9 antagonists for the treatment of congestive heart failure, stroke, ischemic heart disease, etc. For example, reaction of 2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylamine (preparation given) with 1-naphthalenesulfonyl chloride yielded compound III. The latter showed an IC50 = 10 μM in the assay of human urotensin-II-induced CA2+ mobilization in UTR cells.

ACCESSION NUMBER: 2004:718308 HCAPLUS
DOCUMENT NUMBER: 141:243188
TITLE: Preparation of phenylenediamine and thiophene carboxylic amide derivatives as urotensin-II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, Eric C.; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Market, Robert V.
PATENT ASSIGNEE(S): Encysive Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073634	A2	20040902	WO 2004-US4645	20040218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212985	A1	20040902	AU 2004-212985	20040218
CA 2515780	AA	20040902	CA 2004-2515780	20040218
EP 1610753	A2	20060104	EP 2004-712313	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2003-448791P P 20030220
WO 2004-US4645 W 20040218

OTHER SOURCE(S): MARPAT 141:243188

IT **749268-37-9P**, 3-Phenylaminosulfonyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide **749268-38-0P**, 3-Benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)

RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



IT **749268-61-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)

RN 749268-61-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(methoxymethyl)phenylamino]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Apr 2002
GI



I



II



III

AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
DOCUMENT NUMBER: 136:309843
TITLE: Preparation of thiophenes as phosphate transport inhibitors
INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028353	A2	20020411	WO 2001-US31318	20011005
WO 2002028353	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,

US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002013048	A5	20020415	AU 2002-13048	20011005
PRIORITY APPLN. INFO.:			US 2000-238068P	P 20001005
			WO 2001-US31318	W 20011005

OTHER SOURCE(S): MARPAT 136:309843

IT **409361-91-7P 409361-92-8P 409361-93-9P**
409361-94-0P 409361-99-5P 409362-00-1P
409362-01-2P 409362-02-3P 409362-03-4P
409362-04-5P 409362-05-6P 409362-06-7P
409362-11-4P 409362-12-5P 409362-13-6P
409362-14-7P 409362-17-0P 409362-18-1P
409362-19-2P 409362-20-5P 409362-22-7P
409362-28-3P 409362-29-4P 409362-30-7P
409362-31-8P 409362-32-9P 409362-33-0P
409362-34-1P 409362-35-2P 409362-36-3P
409362-37-4P 409362-38-5P 409362-39-6P
409362-40-9P 409362-41-0P 409362-42-1P
409362-43-2P 409362-44-3P 409362-45-4P
409362-46-5P 409362-47-6P 409362-48-7P
409362-49-8P 409362-50-1P 409362-51-2P
409362-52-3P 409362-53-4P 409362-54-5P
409362-55-6P 409362-56-7P 409362-57-8P
409362-58-9P 409362-59-0P 409362-60-3P
409362-61-4P 409362-62-5P 409362-63-6P
409362-64-7P 409362-65-8P 409362-66-9P
409362-67-0P 409362-68-1P 409362-69-2P
409362-70-5P 409362-71-6P 409362-72-7P
409362-73-8P 409362-75-0P 409362-76-1P
409362-77-2P 409362-78-3P 409362-81-8P
409362-82-9P 409362-83-0P 409362-84-1P
409362-85-2P 409362-87-4P 409362-93-2P
409362-95-4P 409362-97-6P 409362-98-7P
409363-00-4P 409363-01-5P 409363-02-6P
409363-03-7P 409363-04-8P 409363-05-9P
409363-06-0P 409363-07-1P 409363-08-2P
409363-10-6P 409363-15-1P 409363-17-3P
409363-19-5P 409363-21-9P 409363-25-3P
409363-27-5P 409363-28-6P 409363-29-7P
409363-30-0P 409363-31-1P 409363-32-2P
409363-35-5P 409363-36-6P 409363-41-3P
409363-51-5P 409363-52-6P 409363-53-7P
409363-54-8P 409363-57-1P 409363-58-2P
409363-59-3P 409363-60-6P 409363-61-7P
409363-62-8P 409363-63-9P 409363-64-0P
409363-65-1P 409363-66-2P 409363-67-3P
409363-69-5P 409363-70-8P 409363-71-9P
409363-72-0P 409363-73-1P 409363-74-2P
409363-75-3P 409363-76-4P 409363-77-5P
409363-78-6P 409363-79-7P 409363-80-0P
409363-81-1P 409363-82-2P 409363-83-3P
409363-84-4P 409363-85-5P 409363-86-6P
409363-87-7P 409363-88-8P 409363-89-9P
409363-90-2P 409363-91-3P 409363-92-4P
409363-93-5P 409363-94-6P 409363-95-7P
409363-96-8P 409363-97-9P 409363-98-0P
409363-99-1P 409364-00-7P 409364-01-8P
409364-02-9P 409364-03-0P 409364-04-1P

409364-05-2P 409364-06-3P 409364-29-0P
409364-31-4P 409364-33-6P 409364-35-8P
409364-37-0P 409364-39-2P 409364-41-6P
409364-43-8P 409364-45-0P 409364-47-2P
409364-49-4P 409364-51-8P 409364-53-0P
409364-54-1P 409364-56-3P 409364-64-3P
409364-65-4P 409364-66-5P 409364-81-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenes as phosphate transport inhibitors)

RN 409361-91-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-92-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-93-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-94-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409361-99-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-00-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-01-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-02-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-03-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-04-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-05-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-06-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-11-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-12-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-13-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-14-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-17-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(trifluoromethyl)phenyl]-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-18-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-19-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 409362-20-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-22-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-28-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-29-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-30-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-phenoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-31-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(hexyloxy)phenyl]-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-32-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-33-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-34-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-acetylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-35-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-benzoylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-36-3 HCAPLUS
CN Benzeneacetic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-37-4 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)



RN 409362-38-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-oxopropyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-39-6 HCAPLUS
CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-40-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(2-hydroxyethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-41-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-42-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(diethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-43-2 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 409362-44-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 409362-45-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(1H-indazol-6-ylamino)sulfonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-46-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409362-47-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(hydroxymethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-48-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-cyclohexylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-49-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-50-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-51-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-52-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-phenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-53-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409362-54-5 HCAPLUS
CN Benzoic acid, 2-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-55-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-56-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,6-difluorophenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-57-8 HCAPLUS
CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409362-58-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-59-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-1,3-benzodioxol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-60-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-61-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-62-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-benzoyl-4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-63-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(1H-indol-2-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-64-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-5-isoquinolinyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-65-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-2-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-66-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-9H-fluoren-2-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-67-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(phenylamino)carbonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-68-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-69-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-2-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-70-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-71-6 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
ethyl ester (9CI) (CA INDEX NAME)



RN 409362-72-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-73-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-75-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409362-76-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-acetylphenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-77-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-78-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 409362-81-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-82-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409362-83-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-84-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(1H-pyrrol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-85-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-87-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-93-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-95-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-97-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-98-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-00-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-01-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-benzotriazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-02-6 HCAPLUS
CN Benzoic acid, 2-methoxy-5-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-03-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methyl-6-benzothiazolyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-04-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(1,3-dihydro-5-isobenzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-05-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-06-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(2-methyl-4-pyrimidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-07-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(5-oxazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-08-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX NAME)



RN 409363-10-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409363-15-1 HCAPLUS
CN Benzoic acid, 4-methoxy-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-17-3 HCAPLUS
CN Benzoic acid, 4-methyl-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-19-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(phenylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-21-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 409363-25-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 409363-27-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-28-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-29-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-30-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(dimethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-31-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-32-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-35-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409363-36-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409363-41-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-51-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(phenylmethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-52-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-3-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-53-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-54-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(methylthio)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-57-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-1-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-58-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-59-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-60-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-61-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chloro-3-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-62-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409363-63-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-64-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-65-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-66-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3-

fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-67-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-69-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-70-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-71-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-72-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-73-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chloro-3,5-dimethylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-74-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-75-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-76-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-77-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-78-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-79-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-80-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-2-methylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-81-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-82-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-83-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-84-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-85-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,6-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-86-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-iodophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-87-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-88-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-89-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-acetylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-90-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-cyanophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-91-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-cyanophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-92-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-93-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-dichloro-4-hydroxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-94-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,5-dimethoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-95-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-96-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methoxy-5-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-97-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluoro-4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-98-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-99-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,5-dimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-00-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-01-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-02-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-ethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-03-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,4,6-trimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-04-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(2-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-05-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(1-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-06-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-29-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 409364-31-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 409364-33-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-35-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-37-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-39-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(hexyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-41-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-43-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-45-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-47-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-49-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-51-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-53-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 409364-54-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-56-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-64-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-(4-fluorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-65-4 HCAPLUS
CN [2,2'-Bithiophene]-5-carboxamide, N-(3-chlorophenyl)-4-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-66-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-chlorophenyl)sulfonyl]amino]-4-methyl- (9CI) (CA INDEX NAME)



RN 409364-81-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 23 Jan 2000
GI



AB The title compds. [I; A1 = (un)substituted phenylene, naphthylene, heteroarylene; ring A2 comprises the carbon atoms which carry the groups C(:X)NH and NHSO2R2 is a benzene, naphthalene, (un)saturated 3-7 membered carbocycle, etc.; R1 = (un)substituted aryl, heterocyclyl, C1-18 alkyl; R2 = (un)substituted aryl, heterocyclyl, C1-10 alkyl, etc.; R3 = H, halo, CF3, etc.; n = 0-2; X = O, NH], useful for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared The compds. I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. Thus, reacting 4-{[2-(4-chlorophenylsulfonyl)-4,5-dimethoxybenzoyl]amino}benzenesulfonyl fluoride (preparation given) with thiomorpholine afforded 65% II which showed 34.8-fold stimulation ([cGMP]test substance/[cGMP]control) at 50 μM.

ACCESSION NUMBER: 2000:53572 HCAPLUS
DOCUMENT NUMBER: 132:93104
TITLE: Preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production
INVENTOR(S): Schindler, Ursula; Schonafinger, Karl; Strobel, Hartmut
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19830430	A1	20000113	DE 1998-19830430	19980708
DE 19903126	A1	20000803	DE 1999-19903126	19990127
CA 2336807	AA	20000120	CA 1999-2336807	19990625
AU 9946160	A1	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002520309	T2	20020709	JP 2000-559082	19990625
JP 3786579	B2	20060614		
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	E	20051115	AT 1999-929318	19990625
NO 2001000013	A	20010301	NO 2001-13	20010102
PRIORITY APPLN. INFO.:			DE 1998-19830430 A	19980708
			DE 1999-19903126 A	19990127
			WO 1999-EP4426 W	19990625

OTHER SOURCE(S): MARPAT 132:93104

IT **254877-23-1P 254877-27-5P 254878-40-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production)

RN 254877-23-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-

thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254878-40-5 HCAPLUS
CN Benzenesulfonyl fluoride, 4-[[[3-[[(4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Jan 2000
GI



I

AB Title compds. [I; A1 = (substituted) phenylene, naphthylene, heteroarylene; A2 = atoms to form Ph, naphthyl, carbocyclyl, heterocyclyl rings; R1 = (substituted) aryl, heterocyclyl, alkyl; R2 = R1, amino; R3 = ≥1 of H, halo, CF3, OH, alkoxy, alkoxyalkoxy, aryloxy, NO2, cyano, amino, CO2H, etc.; X = O, NH, etc.; n = 0-2], were prepared Thus, 4-[[2-(4-chlorphenylsulfonylamino)-4,5-dimethoxybenzoyl]amino]benzenesulfonyl fluoride was heated in thiomorpholine at 90° for 30 min. to give 65% 2-(4-chlorophenylsulfonylamino)-4,5-dimethoxy-N-[4-(thiomorpholin-4-sulfonyl)phenyl]benzamide. The latter at 50 μM gave 34.8-fold stimulation of soluble guanylate cyclase.

ACCESSION NUMBER: 2000:31524 HCAPLUS
DOCUMENT NUMBER: 132:93102
TITLE: Preparation of arylsulfonylaminoarylamides as guanylate cyclase activators.
INVENTOR(S): Schindler, Ursula; Schoenafinger, Karl; Strobel, Hartmut
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19830430	A1	20000113	DE 1998-19830430	19980708
CA 2336807	AA	20000120	CA 1999-2336807	19990625
WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9946160	A1	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
TR 200100147	T2	20010521	TR 2001-200100147	19990625
JP 2002520309	T2	20020709	JP 2000-559082	19990625
JP 3786579	B2	20060614		
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	E	20051115	AT 1999-929318	19990625
EP 1614678	A2	20060111	EP 2005-21577	19990625
EP 1614678	A3	20060322		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

ES 2251200	T3	20060416	ES 1999-929318	19990625
US 6335334	B1	20020101	US 1999-349933	19990708
ZA 2000007486	A	20020104	ZA 2000-7486	20001214
NO 2001000013	A	20010301	NO 2001-13	20010102
US 2002061887	A1	20020523	US 2001-994730	20011128
US 6881735	B2	20050419		
US 2004186145	A1	20040923	US 2004-816143	20040402
JP 2006143737	A2	20060608	JP 2005-343295	20051129

PRIORITY APPLN. INFO.:

DE 1998-19830430	A	19980708
DE 1999-19903126	A	19990127
EP 1999-929318	A3	19990625
JP 2000-559082	A3	19990625
WO 1999-EP4426	W	19990625
US 1999-349933	A3	19990708
US 2001-994730	A3	20011128

OTHER SOURCE(S): MARPAT 132:93102

IT **254877-23-1P 254877-27-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylaminoarylamides as guanylate cyclase activators)

RN 254877-23-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



IT **254878-40-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonylaminoarylamides as guanylate cyclase activators)
RN 254878-40-5 HCAPLUS
CN Benzenesulfonyl fluoride, 4-[[[3-[[(4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	28.08	195.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

STN INTERNATIONAL LOGOFF AT 13:02:31 ON 26 JUN 2006